Issue Date: February 15, 2016 | Web Date: February 10, 2016
Yumanity Therapeutics Reaps $45 Million In Financing
Yumanity Therapeutics, a neuroscience start-up launched in 2014 by high-profile founders, has raised $45 million in its first funding round. The investment endorses the company’s novel approach to tackling Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis—diseases that are frustrating drug development at some of the world’s largest pharma firms.
The large influx of capital is an unusually “big raise” for a company still early in the discovery process, admits CEO Tony Coles, . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society